AbCellera Biologics (ABCL) PT Lowered to $34 at Credit Suisse
Tweet
Share
E-mailGet Alerts ABCL Hot Sheet
Price: $11.36 +0.71%
Rating Summary:
12 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 11 | New: 32
Rating Summary:
12 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 11 | New: 32
Join SI Premium – FREE
Credit Suisse analyst Tiago Fauth lowered the price target on AbCellera Biologics (NASDAQ: ABCL) to $34.00 (from $40.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Sprinklr Inc (CXM) PT Raised to $7.50 at Cantor Fitzgerald
- National Health Investors (NHI) PT Lowered to $80 at Truist Securities
- ONEOK Inc (OKE) PT Raised to $104 at Truist Securities
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
